COVID-19 Antibodies
The IM test is used for the qualitative screening and semi-quantitative determination of heterophile antibodies in serum as an aid in the diagnosis of infectious mononucleosis. IM occurs most often in individuals 15-30 years of age. There are few to no symptoms but is highly contagious.
Nucleocapsid Protein COVID-19 Total Antibody Test
SARS-CoV-2 total nucleocapsid antibody assay detects total nucleocapsid antibodies to IgM, IgA and IgG in human serum or plasma specimens. The total antibody assay indicates recent or prior infection. It is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Individuals may have detectable virus present for several weeks following seroconversion.
Spike Protein COVID-19 Antibody Test
Positive results to antibodies against SARS-CoV-2 are generally indicative of an individual’s current or prior infection with the COVID-19 virus, however, the duration of these antibodies remaining in circulation has not yet been established. These test results should always be considered in the context of a patient’s clinical history, physical examination, epidemiologic exposures and vaccination history before making the final diagnosis.
​
-
IgM isotype antibodies develop within 5 to 7 days and indicates recent infection.
-
IgG isotype antibodies develop after 10 days and remain in circulation longer. It may indicate past infection or vaccine mediated immune response.
-
IgA isotype antibody development is variable in its response and may indicate It may indicate past infection or vaccine mediated immune response.
Rapid Lateral Flow Tests
Additional Tests
Medical and Lab Supplies
Reference Strains and Controls​
Microbiology Products